More Dengue, More Questions by Halstead, Scott B.
D
engue is epidemic or
endemic in virtually
every country in the tropics; it
is even cited in the Guinness
World Records, 2002, as the
world's most important viral
hemorrhagic fever and the
most geographically wide-
spread of the arthropodborne
viruses. As illustrated in this
issue of Emerging Infectious
Diseases, dengue epidemics
are expanding rapidly, as is the literature on the subject.
That dengue was transmitted in the United States for near-
ly 1 year in 2001 (1) should serve as a wake up call to
Americans, most of whom are ignorant of the threat of this
disease. Both the major dengue vectors, Aedes aegypti and
Ae. albopictus, are widely distributed in the continental
United States. 
This emerging disease continues to baffle and challenge
epidemiologists and clinicians. Despite endemicity of 3 or
more different dengue viruses, why does severe dengue
occur in some populations and not in others? Why are chil-
dren principally affected in some areas and adults in oth-
ers? How can severe dengue reliably be recognized early
enough to permit appropriate therapy to be applied?
Recent studies point in the direction of answers to these
questions.
During an infection with any of the 4 dengue viruses,
the principal threat to human health resides in the ability of
the infecting virus to produce an acute febrile syndrome
characterized by clinically significant vascular permeabil-
ity, dengue hemorrhagic fever (DHF). However, because at
onset vascular permeability exhibits only subtle changes,
how can a diagnosis be made early enough to begin life-
saving intravenous treatment? In persons with light skin
color, the standard syphygmomanometer cuff tourniquet
test has been widely used to screen children in outpatient
settings; a positive test result is an early warning of
incipient DHF. Because of genetic diversity among
humans, the tourniquet test as a screening tool requires
widespread evaluation and validation. In a prospective
study of 1,136 Vietnamese children with serologically con-
firmed overt dengue infections, the tourniquet test had a
sensitivity of 41.6%, a specificity of 94.4%, a positive pre-
dictive value of 98.3%, and a negative predictive value of
17.3% (2). A positive result should prompt close observa-
tion, but a negative result does not exclude an ongoing
dengue infection. 
Amore robust screening test could result from the stud-
ies of Wills et al., who measured the size and charge char-
acteristics of proteins leaking through the endothelial sieve
in DHF patients (3). Such changes are caused, presumably,
by a cytokine cascade, as yet incompletely identified.
Their observations suggest that capillaries leak in most
overt dengue infections, but fluid loss is not at levels that
alter cardiovascular status. Quantitative differences in
duration and amount of protein leak demarcate DHF from
dengue fever. Importantly, the authors found increased
amounts of serum proteins, increased differential protein
excretion, and increased amounts of heparan sulfate in the
urine of DHF patients. Detecting protein or heparan sulfate
in acute-phase urine could provide early evidence of
increased vascular permeability.
Humans are not uniformly susceptible to the DHF syn-
drome. HLA gene distribution correlates with increased
susceptibility as well as with increased resistance (4). In
addition, a powerful resistance gene is found in blacks (5).
Importantly, susceptibility to vascular permeability during
a dengue infection is age-related. This conclusion comes
from a study of the age distribution of patients hospitalized
during the 1981 DHF epidemic in Cuba. In that epidemic,
persons 2–50 years of age were exposed to infections with
dengue 1 virus (DENV-1) from 1977 to 1979 and DENV-
2 virus in 1981 at similar rates (6). Thus, age-specific hos-
pitalization and death rates were a measure of intrinsic
susceptibility to vascular permeability during secondary
DENV-2 virus infections. The youngest children were
found to be at greatest risk; rates fell rapidly and were
lowest in older teenagers and young adults, rising again
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Scott B. Halsteadsomewhat in older patients. The susceptibility of young
children to DHF precisely paralleled age-related changes
in microvascular permeability measured in normal chil-
dren and adults.
That cytokines, not virus, damage endothelial cells dur-
ing the course of a dengue infection could be inferred from
a recently published immunopathology study of human tis-
sues from DHF patients (7). Despite in vitro evidence that
dengue viruses infect human endothelial cells, dengue
virus was found to have replicated in vivo in monocytes,
macrophages, and B lymphocytes. While endothelial cells
stained for dengue antigens, this staining was concluded to
be the result of in vivo deposition of virus-antibody com-
plexes but not cellular infection.
Differences in intrinsic virulence are widely believed to
explain the ability of some dengue virus strains to cause
DHF while others do not. Indeed, phenotypic attributes of
avirulent American DENV-2 genotype viruses appear to
correlate with differences in disease severity (8). A differ-
ent explanation was provided by a prospective fever study
in Iquitos, Peru. In 1990, DENV-1 virus entered Iquitos
and became endemic. In 1995, widespread, mostly silent
infections with American genotype DENV-2 were detect-
ed. Many persons infected with DENV-2 had antibodies
elicited by an earlier DENV-1 infection. In contrast to
Cuba, DHF did not develop in any of these secondarily
infected persons. Antibodies to DENV-1 in the sera of
Iquitos residents strongly neutralized American genotype
DENV-2 viruses, but not virulent Asian genotype DENV-2
viruses isolated from DHF epidemics in the Americas (9).
DENV-2 antigenic differences, reflected in heterotypic
neutralization by antibodies to DENV-1, appeared to result
in downregulated infection severity and corresponding
clinical expression. 
In the American tropics, with the exception of Cuba in
1981, most dengue cases were observed initially in adults.
An illustration of this phenomenon is exhibited by the
recent outbreak in Hawaii, where primary infections with
DENV-1 virus produced dengue fever syndrome in adults.
Dengue fever syndrome in susceptible adults may be con-
trasted to the innate susceptibility of children for vascular
permeability syndrome during a secondary dengue virus
infection. In Southeast Asia, the epicenter of DHF epi-
demics in children, dengue infection rates are falling,
resulting in changing epidemiologic patterns of DHF. In
Thailand, for example, the modal age at which children are
hospitalized for DHF has steadily increased over the past
several decades (A. Nisalak, pers. comm.). In addition,
because an increasing number of persons experience their
first dengue infection at an older age, dengue fever cases
are now appearing in adults.
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